Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PODD

Insulet Corporation

Feb 23 • 03:17PM ET

250.21

+8.32 3.44 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM JNJ ABT MDT EW SYK TNDM BSX BAX LIVN

| Held by: VTI VOO IVV VB SPY VO VUG RSP XLV IWP

Index	S&P 500	P/E	71.47	EPS (ttm)	3.50	Insider Own	0.43%	Shs Outstand	70.39M	Perf Week	3.08%
Market Cap	17.61B	Forward P/E	30.96	EPS next Y	8.08	Insider Trans	0.64%	Shs Float	70.08M	Perf Month	-10.64%
Enterprise Value	17.90B	PEG	1.15	EPS next Q	1.20	Inst Own	101.91%	Short Float	2.76%	Perf Quarter	-27.76%
Income	247.10M	P/S	6.50	EPS this Y	27.32%	Inst Trans	-0.64%	Short Ratio	2.19	Perf Half Y	-23.68%
Sales	2.71B	P/B	11.62	EPS next Y	27.72%	ROA	7.87%	Short Interest	1.93M	Perf YTD	-11.97%
Book/sh	21.53	P/C	24.60	EPS next 5Y	27.00%	ROE	18.12%	52W High	354.88 -29.49%	Perf Year	-11.52%
Cash/sh	10.17	P/FCF	46.63	EPS past 3/5Y	275.33% 102.14%	ROIC	9.90%	52W Low	230.05 8.76%	Perf 3Y	-15.92%
Dividend Est.	-	EV/EBITDA	30.49	Sales past 3/5Y	27.54% 24.53%	Gross Margin	72.17%	Volatility	4.77% 3.86%	Perf 5Y	-4.04%
Dividend TTM	-	EV/Sales	6.61	EPS Y/Y TTM	-41.15%	Oper. Margin	17.50%	ATR (14)	10.48	Perf 10Y	784.14%
Dividend Ex-Date	-	Quick Ratio	2.11	Sales Y/Y TTM	30.73%	Profit Margin	9.12%	RSI (14)	43.96	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.78	EPS Q/Q	3.91%	SMA20	-0.46%	Beta	1.42	Target Price	357.64
Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	31.18%	SMA50	-8.38%	Rel Volume	1.24	Prev Close	241.89
Employees	5400	LT Debt/Eq	0.65	Earnings	Feb 18 BMO	SMA200	-17.84%	Avg Volume	880.32K	Price	250.21
IPO	May 15, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.59% 1.93%	Trades		Volume	974,455	Change	3.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	TD Cowen	Hold	$294
Jan-12-26	Downgrade	Barclays	Overweight → Equal Weight	$274
Dec-16-25	Initiated	Evercore ISI	Outperform	$370
Nov-19-25	Upgrade	UBS	Neutral → Buy	$400
Oct-21-25	Resumed	Stifel	Buy	$370
Sep-08-25	Resumed	Oppenheimer	Outperform	$365
Jun-16-25	Initiated	Truist	Buy	$365
May-30-25	Initiated	Goldman	Buy	$380
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$350
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform	$340
Nov-06-24	Initiated	Bernstein	Outperform	$300
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343

Show Previous Ratings

Feb-20-26 05:00AM	Senseonics launches automated insulin dosing system with 1-year CGM (MedTech Dive)
Feb-19-26 08:09AM	PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
12:31AM	PODD Q4 Deep Dive: Type 2 Diabetes Expansion and Innovation Drive Outperformance (StockStory)
Feb-18-26 04:33PM	Stocks Settle Higher on Signs of US Economic Strength (Barchart)
02:00PM	Insulet Corp (PODD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
01:57PM	Loading…
01:57PM	Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars (Benzinga)
12:26PM	Insulet (PODD) Shares Skyrocket, What You Need To Know (StockStory)
11:40AM	Analyst Report: Insulet Corporation (Morningstar Research)
09:36AM	Insulet Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Insulet (PODD) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:37AM	Insulet beats revenue expectations in fourth quarter, shares rise (Investing.com)
07:27AM	Insulet: Q4 Earnings Snapshot (Associated Press Finance)
07:07AM	Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales (StockStory)
07:00AM	Insulet Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
05:35PM	Loading…
Feb-17-26 05:35PM	AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-16-26 10:04PM	Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow (StockStory)
Feb-15-26 06:53AM	Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update (Insider Monkey)
Feb-13-26 04:36PM	Analyst Report: DexCom, Inc. (Morningstar Research)
11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 09:15AM	Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-11-26 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-10-26 07:40AM	Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-05-26 07:00AM	Insulet Launches Omnipod 5 and Omnipod Discover in the Middle East to Transform Diabetes Care (Business Wire)
Feb-02-26 07:50PM	Insulet Corporation (PODD): A Bull Case Theory (Insider Monkey)
Jan-30-26 02:31PM	Reasons Why Hedge Funds Favor Insulet Corp (PODD) (Insider Monkey)
Jan-29-26 09:08PM	Analyst Report: Insulet Corporation (Morningstar Research)
Jan-27-26 09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Affirm Holdings, Alcoa, Block, Coinbase Global,CoreWeave, Datadog, Intuitive Surgical, and More (24/7 Wall St.)
Jan-26-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
07:30PM	Loading…
Jan-23-26 07:30PM	Analyst Report: DexCom, Inc. (Morningstar Research)
Jan-22-26 08:59PM	Analyst Report: DexCom, Inc. (Morningstar Research)
08:24AM	What You Need To Know Ahead of Insulets Earnings Release (Barchart)
Jan-21-26 05:00AM	BVI appoints Jim Hollingshead as CEO (MedTech Dive)
Jan-20-26 07:20PM	Is Insulet (PODD) the Future of Diabetes Management? (Motley Fool)
Jan-15-26 05:26AM	JPM26: Insulet presents optimistic growth plan heading into 2026 (Medical Device Network)
Jan-14-26 12:53PM	Bernstein Reduces Firm's PT on Insulet (PODD) Stock (Insider Monkey)
Jan-12-26 09:49AM	Netflix initiated, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-09-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
06:00AM	Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 (Business Wire)
Jan-08-26 09:33AM	What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? (Insider Monkey)
Jan-06-26 07:00AM	Insulet Redefines Diabetes at CES with "Liveable Technology" - A New Frontier in Human-Centered Connected Health (Business Wire)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Dec-31-25 04:54AM	Best Growth Stocks to Buy for December 31st (Zacks)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-29-25 08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-26-25 12:45PM	3 Reasons Growth Investors Will Love Insulet (PODD) (Zacks)
07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
08:42AM	Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 (Insider Monkey)
07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
01:50AM	Medtronics diabetes spinoff MiniMed files for IPO (MedTech Dive)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 10:32AM	Is Insulet Stock Underperforming the Nasdaq? (Barchart)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
07:00AM	Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 07:54AM	4 Medical Device Stocks to Buy for Healthy Returns in 2026 (Zacks)
07:00AM	Insulet Expands Omnipod U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future (Business Wire)
Dec-11-25 08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 12:45PM	Here is Why Growth Investors Should Buy Insulet (PODD) Now (Zacks)
Dec-08-25 10:34PM	Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers (StockStory)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-04-25 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
08:34AM	Here's Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
07:00AM	Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience (Business Wire)
Dec-01-25 11:34PM	2 Growth Stocks with Explosive Upside and 1 We Find Risky (StockStory) -5.00%
Nov-24-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
05:47AM	Insulet unveils plans for new diabetes devices (MedTech Dive)
05:15AM	Zacks.com featured highlights include Insulet, Sandisk and O-I Glass (Zacks)
Nov-21-25 06:36PM	Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know (StockStory) +5.84%
Nov-20-25 12:30PM	Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day (Business Wire) -9.66%
07:56AM	Insulet Stock: Is Wall Street Bullish or Bearish? (Barchart)
07:03AM	3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns (Zacks)
Nov-19-25 01:45PM	Medtronic Stock Sees RS Rating Pumps Higher (Investor's Business Daily)
09:44AM	DoorDash, Baidu upgraded: Wall Street's top analyst calls (The Fly)
Nov-18-25 11:03PM	3 Reasons We Love Insulet (PODD) (StockStory)
09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
09:31AM	Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs (Zacks)
04:01AM	Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion (Zacks)
Nov-17-25 10:23AM	Do Options Traders Know Something About Insulet Stock We Don't? (Zacks)
09:20AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Nov-13-25 12:20PM	Why Insulet (PODD) Might be Well Poised for a Surge (Zacks)
12:06PM	The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout (Investor's Business Daily)
10:00AM	Best Momentum Stocks to Buy for Nov. 13 (Zacks)
08:46AM	Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
05:09AM	New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More (Zacks)
Nov-12-25 05:54AM	Zacks.com featured highlights include Insulet, Celestica and Innodata (Zacks)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McEvoy Ashley	President and CEO	Feb 20 '26	Buy	239.35	4,300	1,029,205	13,916	Feb 23 08:14 AM
Frederick Wayne A.I.	Director	Dec 15 '25	Sale	293.09	1,851	542,510	2,158	Dec 16 04:04 PM
Frederick Wayne A.I.	Director	Dec 15 '25	Proposed Sale	293.09	1,851	542,500		Dec 15 03:03 PM
STONESIFER TIMOTHY C.	Director	Dec 05 '25	Buy	311.73	962	299,884	4,591	Dec 08 04:02 PM
Manea Dan	Former Officer	Nov 26 '25	Proposed Sale	326.64	4,475	1,461,716		Nov 26 04:31 PM
Manea Dan	Former Officer	Nov 24 '25	Proposed Sale	340.95	2,306	786,228		Nov 24 04:06 PM
Manea Dan	Former Officer	Sep 16 '25	Proposed Sale	337.73	1,347	454,920		Sep 16 01:21 PM
Singh Prem	SVP, Global Operations	Sep 08 '25	Sale	347.49	687	238,726	3,456	Sep 09 04:19 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Option Exercise	241.10	797	192,160	4,687	Sep 09 04:16 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Sale	348.81	797	278,002	3,890	Sep 09 04:16 PM
Cousin Laetitia	Officer	Sep 08 '25	Proposed Sale	348.81	797	278,000		Sep 08 02:07 PM
Singh Prem	Officer	Sep 08 '25	Proposed Sale	347.48	687	238,718		Sep 08 01:31 PM
Benjamin Eric	EVP, CPXO	Aug 21 '25	Sale	332.23	4,263	1,416,296	16,736	Aug 22 04:16 PM
Benjamin Eric	Officer	Aug 21 '25	Proposed Sale	332.23	4,263	1,416,296		Aug 21 10:21 AM
Singh Prem	SVP, Global Operations	Aug 07 '25	Option Exercise	271.28	1,343	364,325	5,486	Aug 08 04:03 PM
Singh Prem	SVP, Global Operations	Aug 07 '25	Sale	320.00	1,343	429,760	4,143	Aug 08 04:03 PM
Singh Prem	Officer	Aug 07 '25	Proposed Sale	320.00	1,343	429,760		Aug 07 11:35 AM
Singh Prem	SVP, Global Operations	Jun 13 '25	Option Exercise	166.62	1,257	209,441	6,470	Jun 16 04:18 PM
Singh Prem	SVP, Global Operations	Jun 13 '25	Sale	300.05	2,327	698,216	4,143	Jun 16 04:18 PM
Manea Dan	SVP, Chief HR Officer	Jun 13 '25	Sale	300.05	1,300	390,065	9,090	Jun 16 04:16 PM
Singh Prem	Officer	Jun 13 '25	Proposed Sale	300.05	2,327	698,216		Jun 13 10:15 AM
Manea Dan	Officer	Jun 13 '25	Proposed Sale	300.05	1,300	390,065		Jun 13 09:45 AM
BORIO LUCIANA	Director	Jun 09 '25	Sale	305.73	481	147,056	3,087	Jun 10 04:17 PM
BORIO LUCIANA	Director	Jun 09 '25	Proposed Sale	305.72	481	147,054		Jun 09 01:08 PM
Hollingshead James	Former Officer	May 16 '25	Proposed Sale	323.10	15,605	5,041,964		May 16 04:40 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Option Exercise	95.43	5,278	503,680	28,458	May 15 04:25 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Sale	318.47	5,278	1,680,885	23,180	May 15 04:25 PM
Hopfield Jessica	Director	May 13 '25	Option Exercise	28.87	5,235	151,134	32,152	May 14 04:15 PM
Hopfield Jessica	Director	May 13 '25	Sale	317.54	5,235	1,662,322	26,917	May 14 04:15 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Option Exercise	92.11	3,001	276,422	23,907	May 14 04:08 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Sale	320.00	3,001	960,320	20,906	May 14 04:08 PM
Kapples John W.	Officer	May 14 '25	Proposed Sale	318.47	5,278	1,680,901		May 14 12:32 PM
Field Mark N	Former Officer	May 13 '25	Proposed Sale	321.31	2,457	789,459		May 13 01:44 PM
Benjamin Eric	Officer	May 13 '25	Proposed Sale	320.00	3,001	960,320		May 13 12:51 PM
Hopfield Jessica	Director	May 13 '25	Proposed Sale	317.54	5,235	1,662,322		May 13 10:19 AM
Frederick Wayne A.I.	Director	Mar 25 '25	Sale	275.00	1,825	501,875	3,231	Mar 26 04:22 PM
Frederick Wayne A.I.	Director	Mar 25 '25	Proposed Sale	275.00	1,825	501,875		Mar 25 10:30 AM
Benjamin Eric	EVP, CPXO	Mar 03 '25	Option Exercise	56.52	5,146	290,873	20,906	Mar 04 04:09 PM

Open in Screener

CVRX

CVRx Inc

Feb 23 • 03:17PM ET

6.80

+0.69 11.29 %

Healthcare • Medical Devices • USA • NASD

Peers: MDT BSX ABT EW SYK ISRG ZBH TFX HOLX ALGN

| Held by: VTI IWM VXF IWO VTWO IWC VTWG DFAS RSSL IWV

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	43.60%	Shs Outstand	26.31M	Perf Week	37.37%
Market Cap	178.91M	Forward P/E	-	EPS next Y	-1.78	Insider Trans	-0.13%	Shs Float	14.84M	Perf Month	3.66%
Enterprise Value	153.70M	PEG	-	EPS next Q	-0.52	Inst Own	31.60%	Short Float	11.07%	Perf Quarter	-25.68%
Income	-53.31M	P/S	3.16	EPS this Y	1.54%	Inst Trans	1.15%	Short Ratio	5.62	Perf Half Y	-10.17%
Sales	56.65M	P/B	4.55	EPS next Y	11.53%	ROA	-44.76%	Short Interest	1.64M	Perf YTD	-4.23%
Book/sh	1.49	P/C	2.36	EPS next 5Y	6.41%	ROE	-96.59%	52W High	14.14 -51.91%	Perf Year	-50.90%
Cash/sh	2.88	P/FCF	-	EPS past 3/5Y	-0.43% -22.44%	ROIC	-59.58%	52W Low	4.30 58.17%	Perf 3Y	-36.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	36.11% 56.40%	Gross Margin	83.99%	Volatility	16.23% 11.21%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.71	EPS Y/Y TTM	24.27%	Oper. Margin	-90.49%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.72	Sales Y/Y TTM	10.45%	Profit Margin	-94.10%	RSI (14)	54.48	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	7.63	EPS Q/Q	-5.64%	SMA20	6.57%	Beta	1.29	Target Price	11.17
Payout	-	Debt/Eq	1.28	Sales Q/Q	4.45%	SMA50	-2.44%	Rel Volume	3.07	Prev Close	6.11
Employees	223	LT Debt/Eq	1.28	Earnings	Feb 12 AMC	SMA200	-10.95%	Avg Volume	292.33K	Price	6.80
IPO	Jun 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.88% 1.56%	Trades		Volume	803,384	Change	11.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-09-25	Downgrade	JP Morgan	Neutral → Underweight	$7
Jan-14-25	Upgrade	William Blair	Mkt Perform → Outperform
Sep-10-24	Initiated	Cantor Fitzgerald	Overweight	$14
Jul-11-24	Reiterated	Lake Street	Buy	$18 → $12
May-01-24	Resumed	Craig Hallum	Buy	$30 → $23
May-01-24	Downgrade	William Blair	Outperform → Mkt Perform
May-01-24	Downgrade	JP Morgan	Overweight → Neutral	$36 → $13
Jan-31-23	Initiated	Lake Street	Buy	$20
Jul-18-22	Initiated	Craig Hallum	Buy	$15
Jul-26-21	Initiated	William Blair	Outperform
Jul-26-21	Initiated	Piper Sandler	Overweight	$26
Jul-26-21	Initiated	Canaccord Genuity	Buy	$30

Show Previous Ratings

Feb-15-26 08:01PM	CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ... (GuruFocus.com)
Feb-13-26 08:30AM	CVRx, Inc. Q4 2025 Earnings Call Summary (Moby) -13.01%
Feb-12-26 06:19PM	CVRx Q4 Earnings Call Highlights (MarketBeat) -6.41%
05:30PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:28PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
Feb-11-26 07:35AM	What To Expect From CVRx Inc (CVRX) Q4 2025 Earnings (GuruFocus.com) -9.12%
Jan-29-26 04:10PM	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 (GlobeNewswire)
Jan-23-26 12:33PM	CVRx Kicks Off One Of The Largest Heart Device Trials In History (Benzinga) +11.43%
Jan-22-26 04:05PM	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population (GlobeNewswire) +8.61%
Jan-12-26 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance (GlobeNewswire) -9.86%
Jan-06-26 08:30AM	CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy (GlobeNewswire)
Dec-22-25 08:30AM	CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 12:03AM	CVRx Inc (CVRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Expansions (GuruFocus.com)
07:10PM	Loading…
Nov-05-25 07:10PM	CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:06PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 08:37AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2025 Result (GuruFocus.com)
08:30AM	CVRx to Present at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-22-25 04:30PM	CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 (GlobeNewswire)
Aug-05-25 03:04AM	CVRx Inc (CVRX) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Strategic Expansion and ... (GuruFocus.com) -9.87%
Aug-04-25 05:20PM	CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:16PM	CVRx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Jul-30-25 10:00AM	Steris (STE) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-29-25 08:30AM	CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-28-25 10:00AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-21-25 04:30PM	CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025 (GlobeNewswire)
Jul-17-25 04:58AM	CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains? (Zacks)
07:30AM	Loading…
Jul-16-25 07:30AM	CVRx Announces Positive News on Outpatient Payment for Barostim (GlobeNewswire) +19.01%
May-28-25 04:30PM	CVRx to Present at the William Blair 45th Annual Growth Stock Conference (GlobeNewswire)
May-09-25 03:40AM	CVRx Inc (CVRX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Sales Force Realignment ... (GuruFocus.com) -38.69%
May-08-25 06:35PM	CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:27PM	CVRx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-07-25 11:20AM	What To Expect From CVRx Inc (CVRX) Q1 2025 Earnings (GuruFocus.com)
May-06-25 10:00AM	908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-25 10:01AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-24-25 04:30PM	CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 (GlobeNewswire) +6.06%
Apr-09-25 08:45AM	CVRx Inc: Overreaction Creates Buying Opportunity (Seeking Alpha) +17.26%
Apr-07-25 04:05PM	CVRx Reports Preliminary First Quarter 2025 Financial Results (GlobeNewswire) -46.27%
Feb-12-25 02:45PM	CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim (GlobeNewswire)
Feb-11-25 09:55AM	CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-07-25 09:55AM	Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know (Zacks)
Feb-05-25 02:14AM	CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses (GuruFocus.com) -7.20%
Feb-04-25 05:45PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.11%
04:49PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Feb-03-25 07:08AM	CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Jan-21-25 04:30PM	CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 (GlobeNewswire) -6.47%
Jan-16-25 10:00AM	CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jan-13-25 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance (GlobeNewswire) +6.14%
Dec-23-24 04:30PM	CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 08:31AM	Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team (Insider Monkey)
Nov-20-24 04:30PM	CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.25%
Nov-04-24 08:00AM	CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 (GlobeNewswire) +12.31%
Oct-30-24 03:14AM	CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com) +31.01%
Oct-29-24 05:50PM	CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:46PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Oct-28-24 09:08AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2024 Result (GuruFocus.com)
Oct-21-24 08:42AM	CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? (Zacks) +8.11%
06:40AM	CVRx announces new CPT Category I codes for Barostim heart failure therapy (Medical Device Network)
Oct-19-24 02:10PM	CVRx announces new CPT Category I codes for Barostim (TipRanks)
Oct-18-24 02:08PM	CVRx announces new CPT Category I codes for Barostim (GlobeNewswire) +17.16%
Oct-15-24 04:30PM	CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 (GlobeNewswire)
Sep-12-24 10:13AM	CVRx touts positive two-year data for heart failure neuromodulation device (Medical Device Network) -6.17%
08:00AM	CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim (GlobeNewswire)
Sep-03-24 08:30AM	CVRx Announces Appointment of Two New Board Members (GlobeNewswire) -8.22%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm (GlobeNewswire) +14.55%
Aug-05-24 07:22PM	Insider Buying Alert: President & CEO Kevin Hykes Acquires 30,000 Shares of CVRx Inc (CVRX) (GuruFocus.com) +6.97%
05:20PM	CVRx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CVRX (PR Newswire)
Aug-02-24 08:00AM	CVRx Announces Increased Inpatient Payment for Barostim Procedure (GlobeNewswire)
Jul-31-24 04:27PM	CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) +7.89%
Jul-29-24 05:40PM	CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.51%
04:38PM	CVRx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Jul-15-24 04:30PM	CVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024 (GlobeNewswire)
Jul-12-24 11:54AM	Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength? (Zacks) +14.22%
Jun-25-24 06:50AM	CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer (GlobeNewswire)
Jun-06-24 05:48AM	CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar? (Zacks) +8.40%
May-22-24 08:30AM	CVRx to Present at the William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-16-24 07:30AM	CVRx Announces Key Senior Leadership Team Hires (GlobeNewswire)
May-01-24 10:45AM	CVRx, Inc. (NASDAQ:CVRX) Q1 2024 Earnings Call Transcript (Insider Monkey) -34.75%
08:39AM	Why Is CVRx (CVRX) Stock Down 32% Today? (InvestorPlace)
07:42AM	Q1 2024 CVRx Inc Earnings Call (Thomson Reuters StreetEvents)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Apr-30-24 08:56PM	CVRX Stock Earnings: CVRx Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:44PM	CVRx Inc (CVRX) Reports Q1 2024 Results: Revenue Growth Amid Challenges (GuruFocus.com)
04:34PM	CVRx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire)
Apr-19-24 11:14AM	CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits (Zacks)
Apr-16-24 04:30PM	CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024 (GlobeNewswire)
Apr-15-24 07:30AM	CVRx announces availability of additional data supporting long-term benefits of Barostim (GlobeNewswire)
Jan-31-24 08:00AM	CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer (GlobeNewswire)
Jan-27-24 11:10AM	CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Jan-26-24 07:14AM	Q4 2023 CVRx Inc Earnings Call (Thomson Reuters StreetEvents) -6.75%
Jan-25-24 05:45PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.72%
04:50PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jain Mudit K.	Director	Feb 20 '26	Buy	6.36	46,800	297,592	980,183	Feb 23 06:00 AM
Jain Mudit K.	Director	Feb 18 '26	Buy	4.64	600	2,785	5,650	Feb 18 05:22 PM
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
Nielsen Kirk G.	Director	May 15 '25	Buy	5.45	10,966	59,795	1,910,134	May 19 06:46 PM
Nielsen Kirk G.	Director	May 13 '25	Buy	5.29	101,413	536,313	1,837,968	May 14 05:27 PM
Nielsen Kirk G.	Director	May 14 '25	Buy	5.23	61,200	320,364	1,899,168	May 14 05:27 PM
Nielsen Kirk G.	Director	May 12 '25	Buy	4.79	25,200	120,670	1,736,555	May 14 05:27 PM
Jain Mudit K.	Director	May 12 '25	Buy	4.66	1,500	6,986	4,900	May 13 07:12 PM
Jain Mudit K.	Director	May 13 '25	Buy	5.26	150	789	5,050	May 13 07:12 PM
Hykes Kevin	PRES & CEO	May 12 '25	Buy	4.84	5,000	24,200	133,000	May 12 07:07 PM

Open in Screener

LXRX

Lexicon Pharmaceuticals Inc

Feb 23 • 03:17PM ET

1.49

+0.02 1.36 %

Healthcare • Biotechnology • USA • NASD

LXRX Lexicon Pharmaceuticals Inc daily Stock Chart

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF SCHA PRFZ VHT SCHB QQQS BTEC

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	55.94%	Shs Outstand	363.40M	Perf Week	13.74%
Market Cap	589.25M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.89%	Shs Float	174.24M	Perf Month	-15.34%
Enterprise Value	538.24M	PEG	-	EPS next Q	-0.07	Inst Own	23.05%	Short Float	14.11%	Perf Quarter	2.76%
Income	-68.58M	P/S	8.32	EPS this Y	73.50%	Inst Trans	-28.76%	Short Ratio	10.23	Perf Half Y	27.35%
Sales	70.86M	P/B	4.51	EPS next Y	-46.49%	ROA	-26.02%	Short Interest	24.58M	Perf YTD	29.57%
Book/sh	0.33	P/C	5.08	EPS next 5Y	28.96%	ROE	-45.92%	52W High	1.83 -18.58%	Perf Year	109.86%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-1.29% -	ROIC	-37.38%	52W Low	0.28 425.39%	Perf 3Y	-39.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	370.72% -37.35%	Gross Margin	98.52%	Volatility	5.65% 9.83%	Perf 5Y	-79.97%
Dividend TTM	-	EV/Sales	7.60	EPS Y/Y TTM	74.58%	Oper. Margin	-81.80%	ATR (14)	0.12	Perf 10Y	-82.87%
Dividend Ex-Date	-	Quick Ratio	5.63	Sales Y/Y TTM	1255.21%	Profit Margin	-96.77%	RSI (14)	57.77	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	5.64	EPS Q/Q	80.42%	SMA20	9.52%	Beta	0.96	Target Price	2.92
Payout	-	Debt/Eq	0.54	Sales Q/Q	710.40%	SMA50	14.65%	Rel Volume	0.82	Prev Close	1.47
Employees	103	LT Debt/Eq	0.53	Earnings	Nov 06 BMO	SMA200	27.95%	Avg Volume	2.40M	Price	1.49
IPO	Apr 07, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.39% 205.04%	Trades		Volume	1,765,207	Change	1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

Feb-06-26 05:17PM	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-30-26 02:58PM	Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones (Insider Monkey) -19.44%
02:50AM	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-29-26 04:31PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:05AM	Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Loading…
Jan-23-26 08:30AM	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary (GlobeNewswire)
Jan-21-26 08:30AM	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +19.08%
Jan-12-26 07:30AM	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:30AM	Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" (GlobeNewswire)
Jan-07-26 08:30AM	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 08:30AM	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 (GlobeNewswire)
Dec-05-25 08:30AM	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum (GlobeNewswire)
Nov-25-25 08:30AM	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences (GlobeNewswire)
Nov-24-25 09:47AM	Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development (Insider Monkey) +5.97%
Nov-11-25 08:30AM	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference (GlobeNewswire) +9.86%
02:30PM	Loading…
Nov-08-25 02:30PM	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:47AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:30AM	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans (GlobeNewswire)
Oct-30-25 08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit (GlobeNewswire)
Oct-08-25 07:59AM	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain (GlobeNewswire) -5.92%
Sep-22-25 04:00PM	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-17-25 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
08:30AM	Loading…
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DEBBANE RAYMOND	Director	Feb 20 '26	Buy	1.48	100,000	147,790	1,804,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 19 '26	Buy	1.44	50,000	71,965	1,704,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 18 '26	Buy	1.32	133,688	176,468	1,654,186	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 17 '26	Buy	1.31	76,857	100,544	1,520,498	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 13 '26	Buy	1.31	57,952	75,877	1,443,641	Feb 18 04:30 PM
Invus Global Management, LLC	Director	Feb 02 '26	Buy	1.30	1,538,462	2,000,001	1,538,462	Feb 04 04:25 PM
Swain Judith L	Director	May 13 '25	Option Exercise	0.00	36,810	0	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	0.00	36,810	0	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	0.00	36,810	0	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	0.00	36,810	0	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	0.00	36,810	0	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	0.00	36,810	0	1,385,689	May 13 05:48 PM

Open in Screener

GF

New Germany Fund Inc

Feb 23 • 02:40PM ET

12.20

-0.03 -0.25 %

Financial • Closed-End Fund - Foreign • USA • NYSE

GF New Germany Fund Inc daily Stock Chart

Held by: CEFS

Index	-	P/E	2.01	EPS (ttm)	6.08	Insider Own	0.04%	Shs Outstand	16.18M	Perf Week	2.61%
Market Cap	197.39M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	16.17M	Perf Month	3.04%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	66.29%	Short Float	0.06%	Perf Quarter	17.42%
Income	-	P/S	56.70	EPS this Y	-	Inst Trans	-	Short Ratio	0.62	Perf Half Y	5.45%
Sales	3.48M	P/B	0.91	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf YTD	6.83%
Book/sh	13.42	P/C	-	EPS next 5Y	-	ROE	-	52W High	12.82 -4.84%	Perf Year	38.32%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	8.78 39.02%	Perf 3Y	31.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	1.87% 1.80%	Perf 5Y	-10.02%
Dividend TTM	0.15 (1.21%)	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	121.16%
Dividend Ex-Date	Dec 30, 2025	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.56	Recom	-
Dividend Gr. 3/5Y	50.98% 136.51%	Current Ratio	-	EPS Q/Q	-	SMA20	0.98%	Beta	0.95	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	7.80%	SMA50	3.39%	Rel Volume	0.59	Prev Close	12.23
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	5.68%	Avg Volume	15.66K	Price	12.20
IPO	Jan 25, 1990	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	8,269	Change	-0.25%

Dec-18-25 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Jul-25-25 04:35PM	Certain DWS Closed-End Funds Announce Extension of Share Repurchases and The Central and Eastern Europe Fund, Inc. Announces Extension of Minimum Period for Partial Advisory Fee Waiver (Business Wire)
Jul-18-25 04:35PM	The New Germany Fund, Inc. Announces Results of the Fund's Annual Meeting of Stockholders (Business Wire)
Jun-30-25 04:35PM	The New Germany Fund, Inc. Announces Results of the Funds Annual Meeting of Stockholders (Business Wire)
May-16-25 04:35PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
02:11AM	Loading…
May-08-25 02:11AM	Germany records trade surplus of 21.1B in March (Seeking Alpha)
May-07-25 05:02AM	Euro Area retail sales rise 1.5% in March (Seeking Alpha)
04:30AM	European markets mixed ahead of Fed's policy meeting (Seeking Alpha)
Apr-22-25 04:35PM	The Central and Eastern Europe Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Mar-27-25 09:00AM	German Stocks Over U.S. Stocks? Not So Fast... (SeekingAlpha)
Mar-20-25 11:00AM	Trump's Tariffs: A timeline of the ongoing global trade tension (SeekingAlpha)
04:36AM	European markets mixed as traders await central bank verdicts (SeekingAlpha)
03:04AM	German PPI rises 0.70% in February, less than expected (SeekingAlpha)
Feb-24-25 04:35PM	The New Germany Fund, Inc. Announces Portfolio Manager Change (Business Wire)
Dec-18-24 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
04:35PM	Loading…
Jul-25-24 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-27-24 04:35PM	The New Germany Fund, Inc. Announces Results of the Fund's Annual Meeting of Stockholders (Business Wire)
May-14-24 04:35PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-19-24 04:30PM	The Central and Eastern Europe Fund, Inc. and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Dec-19-23 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Nov-13-23 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Appointment of New Chairman of the Board (Business Wire)
Jul-28-23 04:35PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-22-23 05:00PM	The New Germany Fund, Inc. Announces Results of the Funds Annual Meeting of Stockholders (Business Wire)
May-24-23 04:35PM	The New Germany Fund, Inc. Announces Portfolio Manager Change (Business Wire)
May-05-23 04:05PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-17-23 05:00PM	The Central and Eastern Europe Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Jan-30-23 05:00PM	The New Germany Fund, Inc. Announces Portfolio Manager Changes (Business Wire)
Dec-20-22 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Jul-29-22 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-23-22 05:00PM	The Central and Eastern Europe Fund, Inc. and The New Germany Fund, Inc. Announce Results of Each Funds Annual Meeting of Stockholders (Business Wire)
05:00PM	Loading…
May-26-22 05:00PM	The New Germany Fund, Inc. Announces Portfolio Manager Change (Business Wire)
May-06-22 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-18-22 04:30PM	The Central and Eastern Europe Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Dec-20-21 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Sep-30-21 03:17PM	Capital Link 20th Annual Closed-End Funds & Global ETFs Forum (GlobeNewswire)
Jul-30-21 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-24-21 06:28PM	The Central and Eastern Europe Fund, Inc. and The New Germany Fund, Inc. Announce Results of Each Funds Annual Meeting of Stockholders (Business Wire)
May-07-21 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-19-21 05:00PM	The Central and Eastern Europe Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Dec-18-20 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Jul-24-20 05:10PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jul-15-20 11:32AM	14 Closed-End Funds That Have Held Their Own in This Wild Year (Barrons.com)
Jun-25-20 05:26PM	The Central and Eastern Europe Fund, Inc. and The New Germany Fund, Inc. Announce Results of Each Funds Annual Meeting of Stockholders (Business Wire)
May-08-20 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-20-20 05:00PM	The Central and Eastern Europe Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Dec-19-19 05:00PM	The Central and Eastern Europe Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Sep-04-19 05:00PM	The New Germany Fund, Inc. Announces Portfolio Manager Update (Business Wire)
Jul-26-19 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-20-19 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
May-10-19 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-23-19 05:00PM	The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Dec-19-18 05:00PM	The Central and Eastern Europe Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Jul-27-18 05:00PM	The New Germany Fund, Inc. Announces Change to the Funds Benchmark (Business Wire)
05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-22-18 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
May-09-18 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-17-18 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Jan-05-18 08:48AM	The 10 Funds Everyone Will Be Buying In 2018 (Forbes)
Dec-28-17 03:56AM	These CEFs Soared Up to 58.8% in 2017 and Theyre Just Getting Started (Harvest Exchange)
Dec-19-17 05:00PM	The Central and Eastern Europe Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Jul-31-17 05:00PM	The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jun-27-17 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
Apr-28-17 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Feb-03-17 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Changes to Board Membership and The New Germany Fund, Inc. Announces Portfolio Manager Change (Business Wire)
Dec-20-16 05:53PM	The Central Europe, Russia and Turkey Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Nov-30-16 01:04PM	NEW GERMANY FUND INC Financials
Oct-21-16 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Changes to Board Membership (Business Wire)
Oct-20-16 05:30PM	Mexico's Banorte posts 16 pct rise in 3rd-qtr profit (Reuters)
Aug-04-16 05:00PM	The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
Jul-25-16 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jul-21-16 05:00PM	The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
Jun-30-16 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Results of Annual Meetings of Stockholders (Business Wire)
May-09-16 05:51PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
Apr-29-16 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders (Business Wire)
Mar-23-16 09:48AM	Capital Link's 15th Annual Closed-End Funds & Global ETFs Forum Thursday, April 21, 2016 - The Metropolitan Club, New York City (Marketwired)
Dec-21-15 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Dec-11-15 12:57PM	Gold Fields (GFI) Stock Rallies, Gold Prices Get a Boost From Falling Dollar (TheStreet.com)
Jul-27-15 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases (Business Wire)
Jul-10-15 05:00PM	The New Germany Fund, Inc. Announces Results of the Funds Annual Meeting of Stockholders (Business Wire)
Jun-26-15 05:00PM	The Central Europe, Russia and Turkey Fund, Inc. and The European Equity Fund, Inc. Announce Results of Each Funds Annual Meeting of Stockholders (Business Wire)
May-08-15 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)
May-01-15 05:13PM	NEW GERMANY FUND INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:01PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Annual Meetings of Stockholders and Adoption of Amended and Restated Bylaws (Business Wire)
Apr-24-15 05:19PM	NEW GERMANY FUND INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc. and The New Germany Fund, Inc. Issue Announcement Regarding Recent Settlements Involving Deutsche Bank and its Affiliates (Business Wire)
Apr-15-15 07:57AM	German Bunds: how low can they go?
Apr-08-15 08:00AM	Capital Link's 14th Annual Closed-End Funds & Global ETFs Forum Thursday, April 23, 2015 -- the Metropolitan Club, New York City (Marketwired)
03:00AM	Annual Report for New Germany Fund, Inc. (Company Spotlight)
Mar-26-15 02:30PM	Germany Is On The Rebound -- Time To Buy?
Mar-03-15 03:00AM	Annual Report for New Germany Fund, Inc. (Company Spotlight)
Dec-19-14 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The New Germany Fund, Inc., and The European Equity Fund, Inc. Make Yearly Distribution Announcements (Business Wire)
Dec-15-14 05:00PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Announce Results of Tender Offer Measurement Period (Business Wire)
Nov-13-14 12:58PM	Webcast Conference on The Central Europe, Russia and Turkey Fund (CEE), The European Equity Fund (EEA), and The New Germany Fund (GF) (Marketwired)
Aug-11-14 06:40PM	What's Carl Icahn Buying? (Barrons.com)
Aug-05-14 03:30PM	CEF Update: News You Can Use (Morningstar)
Jul-28-14 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Extension of Share Repurchases and Adoption of New Discount Management Programs (Business Wire)
Jun-30-14 05:07PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. Announce Results of Tender Offer Measurement Period (Business Wire)
Jun-19-14 05:00PM	The Central Europe, Russia and Turkey Fund, Inc., The European Equity Fund, Inc., and The New Germany Fund, Inc. announce results of each Funds Annual Meeting of Stockholders (Business Wire)
Jun-04-14 05:19PM	The New Germany Fund, Inc. Announces Additional Share Repurchase Authorization (Business Wire)
May-09-14 05:35PM	The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions (Business Wire)

The New Germany Fund Inc. is a closed ended equity mutual fund launched by Deutsche Investment Management Americas Inc. The fund is managed by Deutsche Asset Management International GmbH. It invests in the public equity markets of Germany. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in stocks of small and mid cap companies. The fund benchmarks the performance of its portfolio against the Midcap Market Performance Index. The New Germany Fund Inc. was formed on January 16, 1990 and is domiciled in Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saba Capital Management, L.P.	10% Owner	Feb 19 '26	Buy	12.20	17,044	207,937	2,512,366	Feb 23 12:30 PM
Saba Capital Management, L.P.	10% Owner	Feb 17 '26	Buy	11.94	111,243	1,328,241	2,475,948	Feb 19 11:50 AM
Saba Capital Management, L.P.	10% Owner	Feb 18 '26	Buy	12.25	19,374	237,332	2,495,322	Feb 19 11:50 AM
Saba Capital Management, L.P.	10% Owner	Feb 12 '26	Buy	12.02	1,940	23,319	2,364,705	Feb 17 03:21 PM
Saba Capital Management, L.P.	10% Owner	Feb 09 '26	Buy	12.24	15,646	191,507	2,362,765	Feb 11 01:42 PM
Saba Capital Management, L.P.	10% Owner	Feb 06 '26	Buy	12.22	13,754	168,074	2,347,119	Feb 09 03:25 PM
Saba Capital Management, L.P.	10% Owner	Feb 05 '26	Buy	11.83	5,409	63,988	2,333,365	Feb 09 03:25 PM
Saba Capital Management, L.P.	10% Owner	Feb 04 '26	Buy	12.28	12,802	157,209	2,327,956	Feb 05 12:24 PM
Saba Capital Management, L.P.	10% Owner	Feb 02 '26	Buy	12.19	58,289	710,543	2,315,154	Feb 03 03:01 PM
Saba Capital Management, L.P.	10% Owner	Jan 30 '26	Buy	11.99	4,749	56,941	2,256,865	Feb 02 11:11 AM
Saba Capital Management, L.P.	10% Owner	Jan 13 '26	Sale	12.12	2,000	24,240	2,252,116	Jan 14 03:12 PM
Saba Capital Management, L.P.	10% Owner	Jan 12 '26	Buy	12.08	905	10,932	2,254,116	Jan 13 11:03 AM
Saba Capital Management, L.P.	10% Owner	Jan 08 '26	Buy	12.07	22,290	269,040	2,253,211	Jan 12 09:29 AM
Saba Capital Management, L.P.	10% Owner	Jan 07 '26	Buy	11.96	2,752	32,914	2,230,921	Jan 08 10:52 AM
Saba Capital Management, L.P.	10% Owner	Jan 05 '26	Buy	11.63	17,034	198,105	2,228,169	Jan 06 09:59 AM
Saba Capital Management, L.P.	10% Owner	Jan 02 '26	Buy	11.45	580	6,641	2,211,135	Jan 05 11:41 AM
Saba Capital Management, L.P.	10% Owner	Dec 30 '25	Buy	11.38	6,387	72,684	2,210,355	Jan 02 07:04 PM
Saba Capital Management, L.P.	10% Owner	Dec 31 '25	Buy	11.40	200	2,280	2,210,555	Jan 02 07:04 PM
Saba Capital Management, L.P.	10% Owner	Dec 29 '25	Buy	11.45	8,827	101,069	2,203,968	Dec 30 07:26 PM
Saba Capital Management, L.P.	10% Owner	Dec 26 '25	Buy	11.37	800	9,096	2,195,141	Dec 30 07:26 PM
Saba Capital Management, L.P.	10% Owner	Dec 23 '25	Buy	11.38	14,888	169,425	2,194,341	Dec 29 09:18 PM
Saba Capital Management, L.P.	10% Owner	Dec 22 '25	Buy	11.29	12,966	146,386	2,179,453	Dec 29 09:18 PM
Flannery Fiona	Director	Dec 15 '25	Buy	11.47	872	10,000	872	Dec 23 10:09 AM
Saba Capital Management, L.P.	10% Owner	Dec 19 '25	Buy	11.38	15,973	181,773	2,166,487	Dec 22 11:12 AM
Saba Capital Management, L.P.	10% Owner	Dec 16 '25	Buy	11.35	9,643	109,448	2,146,115	Dec 18 12:08 PM
Saba Capital Management, L.P.	10% Owner	Dec 17 '25	Buy	11.25	4,399	49,489	2,150,514	Dec 18 12:08 PM
Saba Capital Management, L.P.	10% Owner	Dec 15 '25	Buy	11.28	14,355	161,924	2,136,472	Dec 16 12:21 PM
Saba Capital Management, L.P.	10% Owner	Dec 12 '25	Buy	11.25	14,268	160,515	2,122,117	Dec 15 09:38 AM
Saba Capital Management, L.P.	10% Owner	Dec 04 '25	Buy	10.92	24,412	266,579	2,104,779	Dec 08 09:58 AM
Saba Capital Management, L.P.	10% Owner	Dec 05 '25	Buy	11.04	3,070	33,893	2,107,849	Dec 08 09:58 AM
Saba Capital Management, L.P.	10% Owner	Dec 03 '25	Buy	10.88	4,544	49,439	2,080,367	Dec 04 05:27 PM
Saba Capital Management, L.P.	10% Owner	Nov 20 '25	Buy	10.50	11,372	119,406	2,075,823	Nov 24 11:08 AM
Saba Capital Management, L.P.	10% Owner	Nov 17 '25	Buy	10.64	17,717	188,509	2,064,451	Nov 18 07:08 PM
Saba Capital Management, L.P.	10% Owner	Nov 10 '25	Buy	10.56	68,788	726,401	2,046,734	Nov 12 10:35 AM
Saba Capital Management, L.P.	10% Owner	Oct 30 '25	Buy	11.41	11,113	126,799	1,977,946	Nov 03 12:16 PM
Saba Capital Management, L.P.	10% Owner	Oct 28 '25	Buy	11.40	5,431	61,913	1,965,176	Oct 30 04:43 PM
Saba Capital Management, L.P.	10% Owner	Oct 29 '25	Buy	11.12	1,657	18,426	1,966,833	Oct 30 04:43 PM
Saba Capital Management, L.P.	10% Owner	Oct 27 '25	Buy	11.24	5,633	63,315	1,959,745	Oct 28 02:43 PM
Saba Capital Management, L.P.	10% Owner	Aug 25 '25	Buy	11.67	5,927	69,168	1,954,112	Aug 26 09:31 AM
Saba Capital Management, L.P.	10% Owner	Jul 18 '25	Buy	12.01	9,796	117,650	1,948,185	Jul 21 11:31 AM
Saba Capital Management, L.P.	10% Owner	May 28 '25	Buy	11.34	4,806	54,500	1,938,389	May 29 09:58 AM
Saba Capital Management, L.P.	10% Owner	May 20 '25	Buy	11.05	46,117	509,593	1,933,583	May 22 06:27 PM
Saba Capital Management, L.P.	10% Owner	May 19 '25	Buy	10.92	10,300	112,476	1,872,066	May 20 12:38 PM
Saba Capital Management, L.P.	10% Owner	May 15 '25	Buy	10.88	26,057	283,500	1,852,866	May 19 06:51 PM
Saba Capital Management, L.P.	10% Owner	May 16 '25	Buy	10.87	8,900	96,743	1,861,766	May 19 06:51 PM
Saba Capital Management, L.P.	10% Owner	May 12 '25	Buy	10.87	15,824	172,007	1,826,809	May 13 11:04 AM
Saba Capital Management, L.P.	10% Owner	May 08 '25	Buy	10.88	200	2,176	1,810,985	May 12 07:51 PM
Saba Capital Management, L.P.	10% Owner	May 05 '25	Buy	10.81	65,585	708,974	1,810,785	May 06 07:27 PM
Saba Capital Management, L.P.	10% Owner	May 02 '25	Buy	10.66	1,072	11,428	1,745,200	May 05 10:23 AM
Saba Capital Management, L.P.	10% Owner	Apr 29 '25	Buy	10.41	6,926	72,100	1,741,546	May 01 05:58 PM
Saba Capital Management, L.P.	10% Owner	Apr 30 '25	Buy	10.46	2,582	27,008	1,744,128	May 01 05:58 PM
Saba Capital Management, L.P.	10% Owner	Apr 25 '25	Buy	10.35	15,789	163,416	1,734,620	Apr 28 09:55 AM
Saba Capital Management, L.P.	10% Owner	Apr 24 '25	Buy	10.21	2,123	21,676	1,718,831	Apr 28 09:55 AM
Saba Capital Management, L.P.	10% Owner	Apr 22 '25	Buy	10.09	9,949	100,385	1,716,608	Apr 24 12:39 PM
Saba Capital Management, L.P.	10% Owner	Apr 23 '25	Buy	10.20	100	1,020	1,716,708	Apr 24 12:39 PM
Saba Capital Management, L.P.	10% Owner	Mar 06 '25	Buy	9.95	4,925	49,004	1,706,659	Mar 10 09:53 AM
Saba Capital Management, L.P.	10% Owner	Mar 04 '25	Buy	9.29	24,957	231,851	1,701,734	Mar 06 05:03 PM
Saba Capital Management, L.P.	10% Owner	Mar 03 '25	Buy	9.20	12,096	111,283	1,676,777	Mar 04 09:44 AM
Saba Capital Management, L.P.	10% Owner	Feb 28 '25	Buy	8.98	300	2,694	1,664,681	Mar 03 12:22 PM

Open in Screener

PMN

ProMIS Neurosciences Inc

Feb 23 • 03:14PM ET

15.98

-0.11 -0.68 %

Healthcare • Biotechnology • Canada • NASD

PMN ProMIS Neurosciences Inc daily Stock Chart

Peers: LLY BIIB REGN VRTX SAVA IONS ACAD AVXL NBIX PRTA

Index	-	P/E	-	EPS (ttm)	-18.64	Insider Own	16.67%	Shs Outstand	2.15M	Perf Week	4.79%
Market Cap	34.39M	Forward P/E	-	EPS next Y	-6.31	Insider Trans	204.24%	Shs Float	1.79M	Perf Month	72.76%
Enterprise Value	18.96M	PEG	-	EPS next Q	-4.66	Inst Own	71.54%	Short Float	1.06%	Perf Quarter	53.91%
Income	-29.28M	P/S	-	EPS this Y	-757.82%	Inst Trans	-15.18%	Short Ratio	0.11	Perf Half Y	16.43%
Sales	0.00M	P/B	3.74	EPS next Y	65.13%	ROA	-127.41%	Short Interest	0.02M	Perf YTD	134.14%
Book/sh	4.27	P/C	2.23	EPS next 5Y	-	ROE	-355.80%	52W High	39.75 -59.80%	Perf Year	-21.57%
Cash/sh	7.17	P/FCF	-	EPS past 3/5Y	- -	ROIC	-318.73%	52W Low	6.27 154.86%	Perf 3Y	-87.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.85% 13.31%	Perf 5Y	-90.32%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-273.84%	Oper. Margin	-	ATR (14)	1.32	Perf 10Y	-74.02%
Dividend Ex-Date	-	Quick Ratio	1.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.76	EPS Q/Q	-176.86%	SMA20	13.27%	Beta	-0.11	Target Price	34.38
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	50.79%	Rel Volume	0.13	Prev Close	16.09
Employees	7	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	34.26%	Avg Volume	168.13K	Price	15.98
IPO	Jan 16, 2007	Option/Short	No / Yes	EPS/Sales Surpr.	17.24% -	Trades		Volume	19,939	Change	-0.68%

Feb-09-26 08:35AM	Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack (24/7 Wall St.)
Feb-04-26 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -16.29%
Jan-30-26 08:00AM	ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing (GlobeNewswire) +17.95%
Dec-18-25 07:30AM	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease (GlobeNewswire) -5.61%
Dec-10-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk (GlobeNewswire) +12.00%
07:30AM	Loading…
Dec-01-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 (GlobeNewswire)
07:00AM	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-24-25 08:00AM	ProMIS Neurosciences Announces Reverse Stock Split (GlobeNewswire) -22.36%
Nov-12-25 07:00AM	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
Nov-03-25 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-22-25 07:30AM	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-03-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -14.76%
07:00AM	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 (GlobeNewswire)
Aug-13-25 07:00AM	ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
08:00AM	Loading…
Jul-29-25 08:00AM	ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference (GlobeNewswire) -6.67%
Jul-28-25 07:00AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -8.76%
Jul-22-25 07:01AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -26.79%
07:00AM	ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +154.49%
08:00AM	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease (GlobeNewswire)
Jun-17-25 07:00AM	ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
May-12-25 07:30AM	ProMIS Neurosciences Announces First Quarter 2025 Financial Results (GlobeNewswire)
Mar-31-25 07:00AM	ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-24-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference (GlobeNewswire)
Mar-13-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-11-25 07:30AM	ProMIS Neurosciences to Participate in the 37th Annual Roth Conference (GlobeNewswire)
Feb-25-25 07:00AM	ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease (GlobeNewswire) -6.19%
Jan-29-25 07:30AM	ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 10:30AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire)
07:00AM	Loading…
Jan-10-25 07:00AM	ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease (GlobeNewswire)
Nov-26-24 07:00AM	ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-14-24 09:15AM	ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-12-24 07:00AM	ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-30-24 08:00AM	ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire) +5.83%
Oct-13-24 02:58PM	ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now (Insider Monkey)
Sep-12-24 07:00AM	ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences (GlobeNewswire)
Sep-05-24 07:00AM	ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-08-24 07:00AM	ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -11.51%
Aug-06-24 07:00AM	ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology (GlobeNewswire) +18.33%
Aug-01-24 07:00AM	ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-30-24 08:30AM	ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -17.43%
Jul-26-24 08:35AM	ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial (GlobeNewswire) -20.70%
08:30AM	ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing (GlobeNewswire)
May-15-24 09:54AM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 (InvestorPlace) -7.22%
May-14-24 04:01PM	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Apr-30-24 07:00AM	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies (GlobeNewswire)
Apr-09-24 07:00AM	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS (GlobeNewswire)
Apr-04-24 07:00AM	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April (GlobeNewswire)
Apr-01-24 10:53PM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 (InvestorPlace) +7.33% +10.15%
04:15PM	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-11-24 07:00AM	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio (GlobeNewswire)
Feb-22-24 07:00AM	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -10.14%
Jan-22-24 07:00AM	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) +7.24%
Jan-08-24 07:00AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire) +5.45%
Jan-03-24 07:00AM	ProMIS Neurosciences, Inc. Announces Leadership Transition (GlobeNewswire) -7.82%
Dec-20-23 07:00AM	ProMIS Neurosciences Announces Publication on Novel Target for ALS (GlobeNewswire)
Nov-20-23 07:00AM	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease (GlobeNewswire) +6.67%
Nov-14-23 04:30PM	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -12.22% +9.36%
Sep-08-23 07:00AM	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing (GlobeNewswire)
Sep-06-23 12:18PM	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:12PM	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing (GlobeNewswire) -9.14% +20.75%
Aug-14-23 05:33PM	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.33%
Jul-17-23 07:00AM	ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline (GlobeNewswire) +120.28%
Jul-14-23 07:45AM	ProMIS Announces Completion of Continuance (GlobeNewswire)
Jul-10-23 07:55AM	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange (GlobeNewswire) -8.11%
Jun-30-23 08:00AM	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved (GlobeNewswire)
Jun-29-23 08:00AM	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time (GlobeNewswire)
May-15-23 05:00PM	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.16%
May-08-23 09:00AM	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease (GlobeNewswire)
Apr-25-23 05:00PM	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease (GlobeNewswire)
Apr-24-23 07:30AM	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.31%
Apr-10-23 07:30AM	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 (GlobeNewswire)
Mar-29-23 08:30AM	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023 (GlobeNewswire)

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaplan Johanne	Chief Development Officer	Feb 19 '26	Buy	15.35	1,629	25,005	3,941	Feb 23 08:31 AM
ABG Management Ltd.	10% Owner	Feb 03 '26	Buy	12.13	700,741	8,499,988	943,090	Feb 05 07:00 PM
Milbury Max A.	Principal Accounting Officer	Oct 03 '25	Buy	0.49	30,392	14,929	45,389	Oct 06 09:12 AM

Open in Screener

FINS

Angel Oak Financial Strategies Income Term Trust

Feb 23 • 03:17PM ET

13.19

+0.02 0.15 %

Financial • Asset Management • USA • NYSE

FINS Angel Oak Financial Strategies Income Term Trust daily Stock Chart

Peers: GS JPM MS BAC PNC WFC TFC C BK USB

| Held by: FCEF

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-0.45%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	0.20%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	1.93%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.29	Perf Half Y	0.57%
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf YTD	-0.15%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	13.64 -3.30%	Perf Year	-1.57%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	12.21 8.02%	Perf 3Y	2.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.59% 0.92%	Perf 5Y	-23.32%
Dividend TTM	1.35 (10.24%)	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	Feb 13, 2026	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.86	Recom	-
Dividend Gr. 3/5Y	5.73% 1.57%	Current Ratio	-	EPS Q/Q	-	SMA20	-0.39%	Beta	0.22	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-0.04%	Rel Volume	0.60	Prev Close	13.17
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	0.55%	Avg Volume	63.99K	Price	13.19
IPO	May 29, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	34,524	Change	0.15%

Feb-02-26 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares February 2026 Distribution (Business Wire)
Jan-02-26 04:05PM	Angel Oak Financial Strategies Income Term Trust Declares January 2026 Distribution (Business Wire)
Dec-01-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares December 2025 Distribution (Business Wire)
Nov-03-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares November 2025 Distribution (Business Wire)
Oct-02-25 08:00AM	Angel Oak Financial Strategies Income Term Trust Reports Brookfield Asset Management Ltd. Acquires a Majority of Angel Oak Companies, LP (Business Wire)
04:05PM	Loading…
Oct-01-25 04:05PM	Angel Oak Financial Strategies Income Term Trust Declares October 2025 Distribution (Business Wire)
Sep-12-25 09:28AM	Angel Oak Financial Strategies Income Term Trust Announces Recommendations to Vote FOR its New Investment Advisory Agreement from ISS, Glass Lewis and Egan-Jones (Business Wire)
Sep-03-25 04:05PM	Angel Oak Financial Strategies Income Term Trust Files Presentation Showcasing the New Investment Advisory Agreement (Business Wire)
Sep-02-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares September 2025 Distribution (Business Wire)
Aug-26-25 04:00PM	Concerned Investor Issues Letter to Angel Oak Financial Strategies Income Term Trust (FINS) Shareholders Regarding the Need to Vote AGAINST a New Investment Advisory Agreement at Special Meeting (PR Newswire)
Aug-25-25 12:00PM	Angel Oak Financial Strategies Income Term Trust Files Definitive Proxy for Special Meeting (Business Wire)
Aug-01-25 01:00PM	Angel Oak Financial Strategies Income Term Trust Declares August 2025 Distribution (Business Wire)
Jul-29-25 08:00AM	Angel Oak Financial Strategies Income Term Trust Sets Record Date and Date for Special Meeting of Shareholders (Business Wire)
Jul-10-25 04:00PM	Angel Oak Financial Strategies Income Term Trust Announces Certified Results from 2025 Annual Meeting of Shareholders (Business Wire)
Jul-03-25 02:05PM	Angel Oak Financial Strategies Income Term Trust Announces Preliminary Results from Annual Meeting of Stockholders (Business Wire)
04:30PM	Loading…
Jul-01-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares July 2025 Distribution (Business Wire)
Jun-18-25 08:00AM	Oversubscribed FINS Rights Offering Enables Angel Oak Capital Team to Deploy Capital into Higher-Coupon Bank Debt Amid Favorable Market Backdrop (Business Wire)
Jun-02-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares June 2025 Distribution (Business Wire)
May-15-25 08:00AM	Angel Oak Financial Strategies Income Term Trust Announces Preliminary Results of Rights Offering (Business Wire)
Apr-11-25 04:05PM	Angel Oak Financial Strategies Income Term Trust Declares May 2025 Distribution (Business Wire)
04:05PM	Angel Oak Financial Strategies Income Term Trust Announces Rights Offering and Monthly Distribution (Business Wire)
Apr-01-25 06:30PM	Angel Oak Financial Strategies Income Term Trust Declares April 2025 Distribution (Business Wire)
09:23AM	Angel Oak Financial Strategies Income Term Trust Reports Announcement by Angel Oak Companies, LP of Acquisition Transaction (Business Wire)
Feb-07-25 04:00PM	Angel Oak Financial Strategies Income Term Trust Declares March 2025 Distribution (Business Wire)
Feb-03-25 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares February 2025 Distribution (Business Wire)
Dec-03-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares December 2024 Distribution (Business Wire)
Nov-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares November 2024 Distribution (Business Wire)
Oct-01-24 06:50PM	Angel Oak Financial Strategies Income Term Trust Declares October 2024 Distribution (Business Wire)
Sep-03-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares September 2024 Distribution (Business Wire)
Aug-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares August 2024 Distribution (Business Wire)
04:30PM	Loading…
Jul-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares July 2024 Distribution (Business Wire)
Jun-03-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares June 2024 Distribution (Business Wire)
May-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares May 2024 Distribution (Business Wire)
Apr-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares April 2024 Distribution (Business Wire)
Mar-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares March 2024 Distribution (Business Wire)
Feb-01-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares February 2024 Distribution (Business Wire)
Jan-02-24 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares January 2024 Distribution (Business Wire)
Dec-01-23 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares December 2023 Distribution (Business Wire)
Nov-01-23 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares November 2023 Distribution (Business Wire)
Oct-16-23 07:09AM	Angel Oak Financial Strats Income Term's Dividend Analysis (GuruFocus.com)
Oct-02-23 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares October 2023 Distribution (Business Wire)
Sep-01-23 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares September 2023 Distribution (Business Wire)
Aug-01-23 04:30PM	Angel Oak Financial Strategies Income Term Trust Declares August 2023 Distribution (Business Wire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohen Ira P	Director	Feb 20 '26	Buy	13.17	379	4,991	379	Feb 23 09:40 AM
Mullins Andrea	Director	Aug 12 '25	Buy	13.15	7,585	99,756	7,585	Aug 14 03:12 PM
Eldredge William	Chief Compliance Officer	Aug 05 '25	Buy	13.10	1,920	25,152	2,940	Aug 06 06:42 AM
Parks Kevin	Portfolio Manager	Jun 02 '25	Buy	12.83	1,000	12,830	5,667	Jun 03 08:09 AM
Albe Alvin R Jr	Director	May 22 '25	Buy	13.12	20,000	262,492	20,000	May 22 12:28 PM
Eldredge William	Chief Compliance Officer	Apr 14 '25	Buy	13.12	765	10,034	765	Apr 15 03:48 PM

Open in Screener

RCG

RENN Fund Inc

Feb 23 • 03:12PM ET

2.86

+0.05 1.78 %

Financial • Closed-End Fund - Equity • USA • AMEX

Index	-	P/E	5.50	EPS (ttm)	0.52	Insider Own	20.04%	Shs Outstand	7.02M	Perf Week	1.78%
Market Cap	20.07M	Forward P/E	-	EPS next Y	-	Insider Trans	11.24%	Shs Float	5.61M	Perf Month	6.12%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	17.28%	Short Float	0.85%	Perf Quarter	8.94%
Income	-	P/S	47.28	EPS this Y	-	Inst Trans	-	Short Ratio	4.35	Perf Half Y	9.58%
Sales	0.42M	P/B	1.04	EPS next Y	-	ROA	-	Short Interest	0.05M	Perf YTD	11.28%
Book/sh	2.74	P/C	-	EPS next 5Y	-	ROE	-	52W High	2.88 -0.69%	Perf Year	7.86%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	2.11 35.55%	Perf 3Y	64.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.33% 3.78%	Perf 5Y	24.35%
Dividend TTM	0.02 (0.73%)	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	221.35%
Dividend Ex-Date	Dec 18, 2025	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.54	Recom	-
Dividend Gr. 3/5Y	73.80% -	Current Ratio	-	EPS Q/Q	-97.60%	SMA20	4.38%	Beta	0.42	Target Price	-
Payout	2.85%	Debt/Eq	-	Sales Q/Q	32.80%	SMA50	7.32%	Rel Volume	0.68	Prev Close	2.81
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	8.74%	Avg Volume	10.99K	Price	2.86
IPO	Apr 30, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,655	Change	1.78%

Dec-04-25 02:52PM	RENN Fund, Inc. Announces Record Date For Year End Distribution 2025 (ACCESSWIRE)
Apr-02-25 04:25PM	RIV: Massive, Fully Covered Distribution At A Discount (Seeking Alpha)
Dec-16-24 05:40PM	RENN Fund, Inc. Announces Year End Distribution (ACCESSWIRE)
Nov-26-24 04:00PM	RENN Fund, Inc. Announces Record Date for Year End Distribution (ACCESSWIRE) -10.83%
Dec-14-23 02:05PM	RENN Fund, Inc. Announces Year End Distribution (ACCESSWIRE)
12:10PM	Loading…
Dec-04-23 12:10PM	Renn Fund, Inc. Announces Record Date for Year End Distribution (ACCESSWIRE)
May-05-23 08:42AM	Richardson Wealth Advisors Honoured on List of Canada's Top Women Advisors (PR Newswire)
Apr-03-23 10:33AM	RF CAPITAL REPORTS AUA OF $36 BILLION FOR MARCH 2023 AND ADDS THREE NEW ADVISORS (PR Newswire)
Dec-20-22 10:30AM	RENN Fund, Inc. Announces Year-End Distribution (ACCESSWIRE) +8.99%
Dec-09-22 10:35AM	Renn Fund, Inc. Announces Record Date for Year End Distribution (Business Wire)
Apr-05-22 08:00AM	MEDIA ADVISORY - RF CAPITAL TO ANNOUNCE Q1 2022 RESULTS AND HOST VIRTUAL AGM ON MAY 4, 2022 (PR Newswire)
Apr-01-22 03:23PM	RF CAPITAL REPORTS RECORD AUA OF $37.1 BILLION FOR MARCH 2022 (PR Newswire) +6.32%
Mar-30-22 07:30AM	RF Capital Completes Common Share Consolidation (PR Newswire)
Jan-27-22 03:17PM	CORRECTING and REPLACING RENN Fund, Inc. Announces Results of Rights Offering (Business Wire)
Dec-17-21 02:09PM	RENN Fund, Inc. Announces Year-End Distribution (Business Wire)
05:30PM	Loading…
Dec-09-21 05:30PM	RENN Fund, Inc. Announces Record Date for Year End Distribution (Business Wire) -6.02%
Dec-08-21 06:24PM	RENN Fund, Inc. Announces Rights Offering for Shares of Common Stock, Record Date and Summary of Terms (Business Wire)
Dec-03-21 09:52AM	RENN Fund, Inc. Announces Rights Offering for Shares of Common Stock, Record Date and Summary of Terms (Business Wire)
Apr-19-21 07:00AM	Dean Manjuris Joins Richardson Wealth as Vice-Chair to Support Ambitious Growth Agenda (PR Newswire)
Apr-15-21 10:33AM	MEDIA ADVISORY - RF Capital to Announce First Quarter 2021 Results May 10, 2021 (PR Newswire)
07:00AM	Richardson Wealth Named a Top 50 Best Workplace (PR Newswire)
Apr-09-21 09:45AM	RF Capital Board Once Again Determines That it Will Not Engage with Competitor's Unsolicited Proposal (PR Newswire)
Oct-20-20 07:58PM	RENN Fund, Inc. Announces Receipt of Proceeds from Petrohunter Energy Corporation (Business Wire)
Feb-11-19 03:35PM	RENN Fund, Inc. Announces Results of Rights Offering (Business Wire)
Dec-19-18 12:11PM	RENN Fund, Inc. Announces Rights Offering for Shares of Common Stock, Record Date and Summary of Terms (Business Wire)
Jun-30-17 01:03PM	RENN Fund, Inc. Shareholders Approve New Investment Advisor (Business Wire)
Jun-05-17 11:52AM	RENN Fund, Inc. Announces Adjournment of Special Meeting of Shareholders (Business Wire)
May-22-17 08:18AM	RENN Fund Board Recommends Shareholders Vote in Favor of All Proposals Contained in Definitive Proxy Dated April 28, 2017 (Business Wire)
Feb-09-17 04:01PM	MOVES-Barclays, Nasdaq, RenCap, AXA, BC Partners (Reuters)
Oct-19-16 09:00AM	RENN Fund Enters into Letter of Intent with Horizon Kinetics (Business Wire) +5.97%
03:14PM	Loading…
Aug-05-16 03:14PM	RENN Fund Announces Shareholder Approval of Plan of Liquidation and Dissolution (Business Wire)
Jul-25-16 03:08AM	RCG Corp. Ltd. :RCG-AU: Earnings Analysis: For the six months ended December 31, 2015 : July 25, 2016 (Capital Cube)
Jun-29-16 08:00AM	RENN Fund, Inc. Announces Postponement of its Annual Meeting (Business Wire)
Jun-28-16 01:51PM	RENN Fund, Inc. Acknowledges Receipt of Non-Binding Proposal from Etude Capital (Business Wire)
Jun-13-16 02:25PM	Etude Capital Delivers Letter to RENN Fund CEO, Board of Directors (PR Newswire)
May-31-16 10:02AM	[$$] High-security smartphone looks to dial up global elite (Financial Times)
Apr-29-16 01:50PM	Milford biotech slashes IPO size by 63% due to hepatitis B competition (bizjournals.com)
Apr-07-16 08:00AM	Etude Capital Comments on RENN Fund Liquidation (Business Wire)
Apr-05-16 08:00AM	RENN Fund, Inc. Board of Directors Approves Plan of Liquidation and Dissolution (Business Wire) +7.32%
Jan-11-16 01:05PM	The Big 4 Theatre Stocks Underperformed In 2015...Will This Year Be Better? (Benzinga)
Dec-16-15 12:50PM	2015 IPOs a 'disappointment' by nearly every measure (bizjournals.com) +9.05%
11:30AM	One Tampa Bay company stands out in a slow year for this benchmark (bizjournals.com)
Dec-08-15 01:13PM	RENN FUND, INC. Financials
Nov-19-15 03:29PM	How Square, Match Group IPOs affect Triangles tech entrepreneurs (bizjournals.com) -5.31%
Jul-28-15 05:13PM	Move over Juno: This company just had the largest biotech IPO ever (bizjournals.com)
Apr-09-15 12:27PM	Carbylan Therapeutics raises $65M in IPO, stock rises on debut (bizjournals.com)
Apr-06-15 03:25PM	Carbylan Therapeutics revives IPO plans, chops target number (bizjournals.com)
03:00PM	Aduro Biotech hikes IPO target to $93 million (bizjournals.com)
Mar-31-15 07:48PM	GoDaddy tops targets with $440M IPO (bizjournals.com)
10:39AM	GoDaddy IPO this week comes at a slow time for tech offerings (bizjournals.com)
Mar-20-15 12:02AM	SteadyMed raises $40M in IPO that falls far short of expectations (bizjournals.com)
Mar-19-15 03:15PM	New study points to cracks in recent IPO boom (bizjournals.com)
Mar-17-15 03:15PM	SteadyMed hopes to break Bay Area IPO lull with $68.4M offering this week (bizjournals.com)
Mar-11-15 03:39PM	RENN FUND, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-09-15 01:40PM	Carbylan Therapeutics lines up $4M debt financing after putting off $93M IPO (bizjournals.com)
Feb-18-15 11:14AM	Carbylan Therapeutics postpones Wall Street debut amid slowing IPO market (bizjournals.com)
Feb-12-15 09:05AM	Genetic testing firm Invitae tops IPO targets, raises $102M (bizjournals.com)
Feb-09-15 10:55AM	Bay Area life science IPOs hope to get past last week's logjam (bizjournals.com)
Feb-02-15 12:19PM	2 more Bay Area life science IPOs coming this week, Invitae sets terms for next week (bizjournals.com)
Jan-26-15 11:35AM	After big Box debut, next 4 Bay Area IPOs are all in life sciences (bizjournals.com)
Dec-29-14 03:20PM	Year in Review: Houston sees fewer IPOs in 2014 (bizjournals.com)
Dec-26-14 02:47PM	Energy IPOs set a record in 2014 (bizjournals.com)
Dec-22-14 02:40PM	Pair of Columbus companies join in biggest year for IPOs since 2000 (bizjournals.com)
Sep-24-14 09:08PM	Interim for RCG Holdings Ltd. (Company Spotlight)
May-22-14 04:19AM	Weibo and Renren highlight troubles facing Chinese web groups (Financial Times)
Mar-15-13 08:22AM	RENN Global: A Cheap, Interesting And Speculative CEF (Seeking Alpha)
Dec-14-12 05:00PM	RENN Global Entrepreneurs Fund, Inc. Announces Resignation of Chief Financial Officer and Appointment of Acting Chief Financial Officer (Business Wire)
May-04-12 06:46AM	Facebook narrows in on IPO price (bizjournals.com)
Mar-05-12 10:14AM	13 Great Senior Discounts (TheStreet)
Feb-14-12 06:47AM	Investing In Emerging Technologies (Seeking Alpha)
Feb-10-12 11:46AM	Shut up and buy the tech bubble? Heck yeah. (MarketWatch)
Jan-11-12 05:20PM	Two trades for this market (MarketWatch)
Jan-04-12 03:29PM	Cody Willard: One of the ten must-own tech stocks for 2012 (MarketWatch)
10:05AM	Amazon is very oversold and other must-reads (MarketWatch)
Dec-09-11 10:03PM	Chicago broker shows 'em the money post MF Global (Reuters)
Dec-04-11 12:12PM	CEF Weekly Review: World Equity Funds Surge (Seeking Alpha)
Oct-27-11 04:26PM	Stock picks for tech traders and other must-reads (MarketWatch)
Sep-27-11 04:24PM	Investment Industry Regulatory Organization of Canada - Trade Resumption - Almonty Industries Inc. (formerly RCG Capital Inc.) - AII (formerly RCG.P) (PR Newswire)
Sep-06-11 08:39AM	RENN Global Entrepreneurs Fund: Much Risk And Much Appeal (Seeking Alpha)
Aug-03-11 08:30AM	Wall Street 1-2-1 Unveils Confirmed Schedule and Prestigious Speaker Line-Up for Upcoming Event at Ritz-Carlton Hotel Grande Lakes on September 13-16, 2011 (Marketwire)
Jun-29-11 04:41PM	Youku.com shares on a rollercoaster, but that's no surprise (MarketWatch)
Apr-17-11 08:55AM	China's Leading Social Networking Site Files for $531M IPO (Seeking Alpha)
Apr-09-11 08:38PM	[video] Kevin Harrington: Forget Banks, Come to ABC's 'Shark Tank' (TheStreet.com)
Apr-08-11 07:30AM	[video] Kevin Harrington: Forget Banks Come to ABC's Shark Tank (TheStreet.com)
Oct-04-10 01:45PM	[$$] A Look at More Media Stock Picks (TheStreet.com)
Sep-12-10 06:10AM	CEF Weekly Review: Service Economy Slowly Advances (Seeking Alpha)
Sep-09-10 02:21AM	Peter Brimelow: Fund service grinds out gains (MarketWatch)
Apr-19-10 09:00AM	RENN Global Entrepreneurs Fund, Inc. Announces the Annual Meeting and RENN Investor Conference (Business Wire)
Dec-31-09 08:41AM	[$$] 3D Could Make Movie Theater Stocks Pop (Barrons.com)
Jun-16-09 12:39AM	[$$] Is Big Runup That Big a Deal? (Barron's Online)
May-20-09 08:54AM	Shareholders Approve Change to a Registered Non-Diversified Closed-End Fund and Changed the Name to RENN Global Entrepreneurs Fund, Inc. (Business Wire)
May-12-09 12:20PM	RENAISSANCE CAPITAL GROWTH & INCOME FUND III INC Files SEC form 10-Q, Quarterly Report (EDGAR Online)
Apr-22-09 08:53AM	Renaissance Capital Growth & Income Fund III, Inc. Announces its Annual Meeting and RENN Investor Conference (Business Wire)
Apr-02-09 12:06PM	RENAISSANCE CAPITAL GROWTH & INCOME FUND III INC Files SEC form 10-K/A, Annual Report (EDGAR Online)
Mar-30-09 04:27PM	RENAISSANCE CAPITAL GROWTH & INCOME FUND III INC Files SEC form 10-K, Annual Report (EDGAR Online)
Feb-20-09 01:50PM	Renaissance Capital Changes Special Shareholders Meeting Date (Business Wire)
Jan-09-09 08:15AM	RCG Board of Directors Recommends Important Structure Change for The Fund (Business Wire)
Nov-12-08 12:22PM	RENAISSANCE CAPITAL GROWTH & INCOME FUND III INC Files SEC form 10-Q, Quarterly Report (EDGAR Online)
Sep-26-08 08:15AM	Renaissance Capital Announces Third Quarter Distribution of $0.10 Per Share (Business Wire)
Aug-29-08 04:30PM	RENAISSANCE CAPITAL GROWTH & INCOME FUND III INC Files SEC form 8-K, Other Events (EDGAR Online)

RENN Fund, Inc. is a closed ended equity mutual fund launched by RENN Capital Group, Inc. The fund is co-managed by Horizon Kinetics Asset Management LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating across diversified sectors. It seeks to invest in stocks of small-cap and mid-cap companies. The fund employs a fundamental analysis with a bottom-up stock picking approach to create its portfolio. It was formerly known as RENN Global Entrepreneurs Fund, Inc. RENN Fund, Inc. was formed on January 20, 1994 and is domiciled in the United States.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STAHL MURRAY	President/Co-Portfolio Manager	Feb 20 '26	Buy	2.84	774	2,198	358,682	Feb 23 12:06 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 20 '26	Buy	2.84	360	1,022	149,534	Feb 23 12:06 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 19 '26	Buy	2.88	774	2,229	358,386	Feb 20 11:50 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 19 '26	Buy	2.88	360	1,037	149,174	Feb 20 11:50 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 18 '26	Buy	2.75	774	2,128	358,090	Feb 19 12:20 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 18 '26	Buy	2.75	360	990	148,814	Feb 19 12:20 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 17 '26	Buy	2.77	774	2,144	357,794	Feb 18 11:14 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 17 '26	Buy	2.77	360	997	148,454	Feb 18 11:14 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 13 '26	Buy	2.83	774	2,190	357,498	Feb 17 10:52 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 13 '26	Buy	2.83	360	1,019	148,094	Feb 17 10:52 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 12 '26	Buy	2.73	774	2,113	357,202	Feb 13 11:02 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 12 '26	Buy	2.73	360	983	147,734	Feb 13 11:02 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 11 '26	Buy	2.65	774	2,051	356,906	Feb 12 10:58 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 11 '26	Buy	2.65	360	954	147,374	Feb 12 10:58 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 10 '26	Buy	2.71	774	2,098	356,610	Feb 11 12:34 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 10 '26	Buy	2.71	360	976	147,014	Feb 11 12:34 PM
DOYLE PETER	Co-Portfolio Manager	Dec 18 '25	Buy	2.60	300	780	300	Feb 10 02:27 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 09 '26	Buy	2.68	774	2,074	356,314	Feb 10 10:25 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 09 '26	Buy	2.68	360	965	146,654	Feb 10 10:25 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 06 '26	Buy	2.70	774	2,090	356,018	Feb 09 11:36 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 06 '26	Buy	2.70	360	972	146,294	Feb 09 11:36 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 05 '26	Buy	2.64	774	2,043	355,722	Feb 06 11:31 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 05 '26	Buy	2.64	360	950	145,934	Feb 06 11:31 AM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 04 '26	Buy	2.73	774	2,113	355,426	Feb 05 01:05 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 04 '26	Buy	2.73	360	983	145,574	Feb 05 01:05 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 03 '26	Buy	2.74	774	2,121	355,130	Feb 04 12:13 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 03 '26	Buy	2.74	360	986	145,214	Feb 04 12:13 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 02 '26	Buy	2.75	774	2,128	354,834	Feb 03 03:24 PM
STAHL MURRAY	President/Co-Portfolio Manager	Feb 02 '26	Buy	2.75	360	990	144,854	Feb 03 03:24 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 30 '26	Buy	2.62	774	2,028	354,538	Feb 02 03:34 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 30 '26	Buy	2.62	360	943	144,494	Feb 02 03:34 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 29 '26	Buy	2.72	774	2,105	354,242	Jan 30 11:23 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 29 '26	Buy	2.72	360	979	144,134	Jan 30 11:23 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 28 '26	Buy	2.66	774	2,059	353,946	Jan 29 01:39 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 28 '26	Buy	2.66	360	958	143,774	Jan 29 01:39 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 27 '26	Buy	2.70	774	2,090	353,650	Jan 28 11:21 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 27 '26	Buy	2.70	360	972	143,414	Jan 28 11:21 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 26 '26	Buy	2.70	774	2,090	353,354	Jan 27 12:14 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 26 '26	Buy	2.70	360	972	143,054	Jan 27 12:14 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 23 '26	Buy	2.70	774	2,090	353,058	Jan 26 12:29 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 23 '26	Buy	2.70	360	972	142,694	Jan 26 12:29 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 22 '26	Buy	2.70	774	2,090	352,762	Jan 23 12:37 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 22 '26	Buy	2.70	360	972	142,334	Jan 23 12:37 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 21 '26	Buy	2.70	774	2,090	352,466	Jan 22 12:36 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 21 '26	Buy	2.70	360	972	141,974	Jan 22 12:36 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 20 '26	Buy	2.69	774	2,082	352,170	Jan 21 11:12 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 20 '26	Buy	2.69	360	968	141,614	Jan 21 11:12 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 16 '26	Buy	2.72	774	2,105	351,874	Jan 20 01:42 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 16 '26	Buy	2.72	360	979	141,254	Jan 20 01:42 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 15 '26	Buy	2.64	774	2,043	351,578	Jan 16 11:40 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 15 '26	Buy	2.64	360	950	140,894	Jan 16 11:40 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 14 '26	Buy	2.68	774	2,074	351,282	Jan 15 11:04 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 14 '26	Buy	2.68	360	965	140,534	Jan 15 11:04 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 13 '26	Buy	2.65	774	2,051	350,986	Jan 14 01:14 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 13 '26	Buy	2.65	360	954	140,174	Jan 14 01:14 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 12 '26	Buy	2.61	774	2,020	350,690	Jan 13 10:38 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 12 '26	Buy	2.61	360	940	139,814	Jan 13 10:38 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 09 '26	Buy	2.60	774	2,012	350,394	Jan 12 03:04 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 09 '26	Buy	2.60	360	936	139,454	Jan 12 03:04 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 08 '26	Buy	2.60	774	2,012	350,098	Jan 09 02:11 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 08 '26	Buy	2.60	360	936	139,094	Jan 09 02:11 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 07 '26	Buy	2.64	774	2,043	349,802	Jan 09 11:52 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 07 '26	Buy	2.64	360	950	138,734	Jan 09 11:52 AM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 06 '26	Buy	2.60	774	2,012	349,506	Jan 07 02:53 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 06 '26	Buy	2.60	360	936	138,374	Jan 07 02:53 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 05 '26	Buy	2.64	774	2,043	349,210	Jan 06 12:46 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 05 '26	Buy	2.64	360	950	138,014	Jan 06 12:46 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 02 '26	Buy	2.59	774	2,005	348,914	Jan 05 03:59 PM
STAHL MURRAY	President/Co-Portfolio Manager	Jan 02 '26	Buy	2.59	360	932	137,654	Jan 05 03:59 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 31 '25	Buy	2.62	774	2,028	348,618	Jan 02 11:22 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 31 '25	Buy	2.62	360	943	137,294	Jan 02 11:22 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 30 '25	Buy	2.61	774	2,020	348,322	Dec 31 10:32 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 30 '25	Buy	2.61	360	940	136,934	Dec 31 10:32 AM
Allen Anita L	Director	Dec 29 '25	Buy	2.64	5	13	658	Dec 31 10:26 AM
Russell Grimaldi	CCO & Secretary	Dec 29 '25	Buy	2.63	3	8	415	Dec 31 10:08 AM
Kesslen Jay H	Vice-President	Dec 29 '25	Buy	2.63	17	45	42,880	Dec 31 10:07 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 29 '25	Buy	2.65	774	2,051	348,026	Dec 30 12:20 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 29 '25	Buy	2.65	360	954	136,574	Dec 30 12:20 PM
Brennan Alice C	Director	Dec 29 '25	Buy	2.63	19	50	2,369	Dec 30 10:36 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 26 '25	Buy	2.65	774	2,051	347,730	Dec 29 11:45 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 26 '25	Buy	2.65	360	954	136,214	Dec 29 11:45 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 24 '25	Buy	2.65	774	2,051	347,434	Dec 29 11:12 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 24 '25	Buy	2.65	360	954	135,854	Dec 29 11:12 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 23 '25	Buy	2.65	774	2,051	347,138	Dec 29 11:08 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 23 '25	Buy	2.65	360	954	135,494	Dec 29 11:08 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 22 '25	Buy	2.60	774	2,012	346,842	Dec 23 04:10 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 22 '25	Buy	2.60	360	936	135,134	Dec 23 04:10 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 19 '25	Buy	2.65	774	2,051	346,546	Dec 22 11:19 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 19 '25	Buy	2.65	360	954	134,774	Dec 22 11:19 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 18 '25	Buy	2.65	774	2,051	346,250	Dec 19 10:56 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 18 '25	Buy	2.65	360	954	134,414	Dec 19 10:56 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 17 '25	Buy	2.65	774	2,051	345,954	Dec 18 11:07 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 17 '25	Buy	2.65	360	954	134,054	Dec 18 11:07 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 16 '25	Buy	2.64	774	2,043	345,658	Dec 17 12:16 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 16 '25	Buy	2.64	360	950	133,694	Dec 17 12:16 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 15 '25	Buy	2.65	774	2,051	345,362	Dec 16 12:23 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 15 '25	Buy	2.65	360	954	133,334	Dec 16 12:23 PM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 12 '25	Buy	2.61	774	2,020	345,066	Dec 15 10:36 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 12 '25	Buy	2.61	360	940	132,974	Dec 15 10:36 AM
STAHL MURRAY	President/Co-Portfolio Manager	Dec 11 '25	Buy	2.60	774	2,012	344,770	Dec 12 11:14 AM

PODD

Insulet Corporation

CVRX

CVRx Inc

LXRX

Lexicon Pharmaceuticals Inc

GF

New Germany Fund Inc

PMN

ProMIS Neurosciences Inc

FINS

Angel Oak Financial Strategies Income Term Trust

RCG

RENN Fund Inc

Upgrade your FINVIZ experience